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Zusammenfassung
Hintergrund: Die Verwendung von Arzneipflanzen ist ein Eckpfei-
ler der traditionellen chinesischen Medizin (TCM). Dennoch exis-
tiert immer noch zu wenig Wissen über deren Risiken und Si-
cherheit. Aus diesem Grunde hat die erste deutsche Klinik für 
TCM Bad Kötzting zum Schutz der Patienten ein Programm zur 
Qualitätssicherung der chinesischen Arzneidrogen und deren 
systematischen Erfassung entwickelt und eingeführt. Methodik: 
Alle in der Zeit vom 1.9.2012 bis 31.12.2013 in die Klinik angelie-
ferten TCM-Arzneidrogen wurden in das Qualitätssicherungspro-
gramm einbezogen und auf mikrobielle Kontamination, Aflato-
xine, Pestizide und Schwermetalle untersucht. Durch eine syste-
matische Laborerfassung von Leberenzymen aller aufgenomme-
nen Klinikpatienten wurden mögliche Leberwertverän derungen 
dokumentiert, alle verordneten Arzneimittel erfasst und bei Auf-
treten von möglichen Leberschäden eine Kausalitätsbewertung 
anhand der leberspezifischen CIOMS-Skala durchgeführt. Schließ-
lich wurden subjektiv unerwünschte Therapiewirkungen über ein 
webbasiertes Gesundheitsdossier dokumentiert. Ergebnisse: In 5 
von 23 Arzneimittel-Chargen (21,7%) wurde eine mikrobielle Be-
lastung (n = 2), Pestizide (n = 2) und Schwermetalle (n = 1) gefun-
den. Die Drogen wurden auf Identität und Reinheit untersucht. 
Alle im Untersuchungszeitraum in die Klinik aufgenommenen 
Patienten (n = 994) mit einem Durchschnittsalter von 52,6 Jahren 
und einem Frauenanteil von 72,6% wurden in die Analyse einge-
schlossen. 448 Patienten (45,1%) klagten über mindestens ein 
unerwünschtes Ereignis, wobei 13,6% über gastrointestinale Be-
schwerden, 10,8% über neurovegetative Störungen, 8,8% über 
vorübergehende Schmerz-Verschlimmerungen, 5,9% über Durch-
fälle, 1,6% über Übelkeit und 0,5% über Erbrechen klagten. In den 
systematischen Laborkontrollen fanden sich 6 Patienten mit min-
destens 2-fach erhöhten GPT-Leberenzymwerten ohne überzeu-
genden Kausalitätshinweis auf bestimmte TCM-Drogen. Schluss-
folgerung: Gelegentliche Erhöhungen von Leberenzymwerten als 
Hinweis auf potentielle Leberschäden durch TCM-Arzneimittel 
können auftreten. Die Patienten sollten auf die Möglichkeit des 
Auftretens von gastrointestinalen Beschwerden und von Leber-
schäden hingewiesen werden. 
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Traditional Chinese Medicine · Hepatotoxicity · Herb-induced 
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Summary
Background: The use of drugs derived from plants is a corner-
stone of Traditional Chinese Medicine (TCM). Yet, too little is 
known about risk and safety of Chinese medicinal drugs (CMD). 
Therefore, the TCM hospital Bad Kötzting has developed a qual-
ity control and complication screening programme in order to 
ensure a safe administration of TCM drugs to their patients. 
Methods: All Chinese medicinal drugs delivered to the hospital 
between September 1, 2012 and December 31, 2013 entered the 
quality control program and were screened for microbial con-
tamination, aflatoxin, pesticides and heavy metals. A routinely 
applied complication screening programme monitored liver en-
zymes in all patients. Case causality assessment by CIOMS scale 
and identification of admitted herbs were conducted. Addition-
ally, side effects of patients were identified by a routinely per-
formed web-based documentation system. Results: In 5 of 23 in-
vestigated samples (21.7%) the initial testing showed microbial 
contamination (2), pesticide (2) and heavy metals (1). The drugs 
were tested for authenticity and adulterations, respectively. All 
994 patients (mean age 52.6 years; 72.6% female) admitted were 
available for analysis. 448 (45.1%) of all patients reported having 
perceived at least one side effect of treatment. They experienced 
mainly gastrointestinal symptoms (13.6%), neurovegetative 
symptoms (10.8 %), temporary deteriorations of pain (8.8%), di-
arrhoea (5.9%), nausea (1.6%) and vomiting (0.5%). Further, 6 pa-
tients with a more than 2-fold elevation (compared to maximum 
normal value or elevated admission values) of ALT were found in 
the systematic laboratory control with a non-conclusive causality 
assessment for TCM-drugs. Conclusion: Approximate incidence 
rates and analysed drugs associated with liver damage revealed 
a low rate of liver injury. Patients should be informed of the gas-
trointestinal symptoms caused by and potential hepatotoxicity of 
TCM herbs. 
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Background
Between 1991 and 2011, German social health insurance com-
panies have agreed to reimburse the inpatient treatment at TCM 
hospital Bad Kötzting if patient characteristics, treatments, out-
comes and side effects were continuously evaluated. The investiga-
tions were performed in collaboration with the Centre of Comple-
mentary Medicine and Naturopathy (CoCoNat), Technical Uni-
versity of Munich, and Centre of Pharma Research, University of 
Munich. The most important therapeutic part of TCM is Chinese 
medicinal drugs (CMD). They are widely used in Asian communi-
ties throughout the world for a broad array of conditions [1]. CMD 
compounds are of herbal and non-herbal nature and commonly 
prescribed concurrently. The medications are usually adminis-
trated as decoctions (tang). A few of them are served as syrups 
(tang jiang) and medicinal wines (Jiu). Although Chinese drug 
remedies appear to be relatively safe they are not free of risks, and a 
number of severe adverse events have been reported [2–7]. A few 
can cause hepatic injury when given in high concentrations, and 
some even when used in recommended doses. Patients treated with 
CMD can be at risk when treated with certain, potentially harmful 
products (e.g. ephedra). Also pharmacological as well as toxicologi-
cal interactions with Western medical interventions are sources of 
potential complications [8]. In a former study, several cases of tem-
porary moderate liver enzyme elevations were observed [9, 10]. It 
is still unclear to what extend this occurs in a clinical setting. For 
that reason and because of scientific interest and safety issues, the 
TCM hospital Bad Kötzting has developed a routinely applied 
complication screening (CSP) and quality control programme 
(QCP). CSP consists of a patient reporting outcome system for un-
desired effect and a standardised laboratory programme for detect-
ing increased laboratory values of liver enzymes. All CMD deliv-
ered to the hospital are mainstreamed into the quality control pro-
gramme. This safety proof aims mainly to exclude drugs which 
might contain e.g. toxic constituents, possess minor general quality 
or show contaminations.
Aim
To exemplify quality and safety measures for CMD adminis-
tered at the TCM hospital Bad Kötzting. Results of preclinical qual-
ity proof of drugs, reported side effects and investigated liver en-
zyme elevations should be documented and discussed. 
Setting 
TCM hospital Bad Kötzting is equipped with 76 beds for inpa-
tients; 8 Chinese physicians trained at the University of Chinese 
Medicine in Beijing (China) and one pharmacist collaborate with 6 
German physicians. Patients can be referred to the hospital directly 
by their general practitioner. From the regular monitoring of the 
treatment process in the TCM hospital it is known that almost all 
patients in the hospital are usually treated with traditional Chinese 
drugs. This treatment usually goes along with acupuncture, Chi-
nese manual and relaxation therapy. Drugs are given as raw mate-
rials in the form of decoctions and in rare cases as alcohol-based 
solutions. Number of prescriptions and of all single drugs as well as 
duration of treatment is documented systematically. Western ther-
apies are continued or prescribed if necessary. 
Methods
Preclinical Quality Control of TCM Medicinal Drugs
Before the TCM drugs can be routinely administered to the patients, all of 
them have to pass a comprehensive drug control program. To exclude possible 
falsifications and adulterations of herbal drugs, quantifiable HPLC-peaks and 
coloured TLC photographs were used for safety and botanical authenticity 
proof. Further investigations, such as chemical reaction, macro- and microscopy 
of the drugs, were performed. Special constituents were identified by HPLC, UV 
spectroscopy, titration and gravimetry according to the German pharmacopoeia 
Deutsches Arzneibuch (1996) and the pharmacopoeia of the People’s Republic of 
China (English edition, 1992; 2005; 2010). This procedure was also applied to 
any herbal drug combination developed by mixing several individual drugs. In 
such cases, microscopy, TLC and/or HPLC analysis certificates were presented 
for individual drugs in order to confirm their authenticity. Therefore, 3–5 drugs 
from various regions of China were investigated for each species to avoid confu-
sion. Most of the plant drugs were screened for microbial contamination 
(TAMC, TYMC, salmonella, Escherichia coli) aflatoxin (B1, B2, G1, G2) pesti-
cides residues and heavy metals (Pb, Cd, Hg, As). The corresponding necessary 
tests required special laboratories in which they were performed prior to all 
other quality investigations. For the European Herbal Drug Regulatory Author-
ity, the following limits for heavy metals are mandatory: lead 5 mg/kg, cadmium 
0.9 mg/kg, mercury 0.2 mg/kg, arsenic 2.0 mg/kg. These standards are not man-
datory for China. For all test certificates, the following basis was set: for microbi-
ology Ph. Eur 2.6.31; for heavy metal contaminants recommendation Ph. Eur 
01/2012; for the requirements of pesticides Ph. Eur 6.1, 2.8.13 and for aflatoxin 
the aflatoxins ban-V. In relation to TCM drugs without testing requirements for 
DC-HPLC fingerprint analysis of identity, ad hoc tests took place at the Center 
for Drug Research of the Ludwig-Maximilians University Munich.
Complication Screening Programme
As part of the routine quality assurance programme, all patients were asked 
to fill out a web-based questionnaire at admission to the hospital, at discharge 
and 6 months after discharge, anonymously. The entries were supported by an 
online health portal, named VITERIO (Virtual Tool for Education, Reporting, 
Information and Outcome). 
An ethical review board was not involved because of the strictly routine 
character of the outcome study as part of a quality assurance programme. All 
legal obligations for the protection of personal data were met, and patients gave 
written informed consent when entering VITERIO.
At discharge, patients were asked to provide information on perceived side 
effects, i.e. to describe these complaints, symptoms and findings within the elec-
tronic documentation system. Furthermore, participants were asked what might 
have caused their complaints: TCM decoctions, acupuncture, tuina or others. 
All inpatients discharged between September 1, 2012, to December 31, 2013 
who had been treated with traditional Chinese drugs received routine blood 
sampling at admission (or not later than one day after admission) and in the last 
3 days before discharge. We investigated the frequency of clinically relevant ele-
vated liver enzymes in all consecutive patients treated at the hospital. The en-
zymes assessed routinely were aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT). An elevated liver enzyme was defined as any elevation 
beyond the normal range in patients with normal values at admission, or any el-
evation beyond admission values in patients with elevated values at admission. 
Clinically relevant elevations were categorised as multiples of the upper normal 
limit (N) in ‘up to 2-fold’, and ‘more than 2-fold’ (beyond maximum normal 
value or elevated admission values). Liver injury was assumed as increased ALT 
activities of at least 2 N, with N as the upper limit of normal [3, 11]. The files of 
patients with more than 2-fold elevation of ALT were further scrutinised. Diag-
nosis, treatment (Western and all TCM drugs), duration of treatment, indica-
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tions of previous liver damage and follow-up data were extracted using a stand-
ard form, adjusted to the liver-specific Council for International Organisation of 
Medical Sciences (CIOMS) scale. Case data were used for causality assessment 
by two independent physicians (D.M., S.H.) and categorised according to the 
items of the CIOMS scale. Final score of CIOMS may range from –9 to +14 
points; resulting causality levels are defined as follows: ≤ 0 points = excluded; 
1–2 = unlikely; 3–5= possible; 6–8 = probable; ≥ 9 = highly probable [3, 11].
Results
Quality Control Program
From September 1, 2012 until end of 2013, all 23 samples of 
drugs delivered to the hospital were documented and tested. In 5 
samples (21.7%) the initial testing showed microbial contamina-
tion (n = 2), pesticides (n = 2) and heavy metals (n = 1); besides, no 
falsifications and adulterations could be found. Dicofol (1.6 mg/kg 
and 3.6 mg/kg respectively vs. upper limit of normal ≤ 0.5 mg/kg) 
and fenpropathrin (0.05 mg/kg vs upper limit of normal ≤ 0.03 
mg/kg) were the most frequent pesticides. Further, contents of lead 
(Pb) in lonicerae flos were slightly increased, and microbial enu-
meration tests (TAMC, total aerobic microbial count; TYMC, total 
yeast/ mold count) showed elevated levels of colony count. All con-
taminated drugs were excluded from the routine administration. 
Table 1 shows the results of all investigations. 
Complication Screening Program
We surveyed 994 consecutive patients treated with TCM drugs 
at the hospital. Seventy-three percent of patients were female, the 
mean (SD) age was 53.5 (12.8) years, most of them experienced 
psychosomatic diseases, and the mean (SD) hospital stay was 26.2 
(5.2) days. Additional diagnoses were e.g. back pain, hypertension 
and sleep disturbances (table 2). 
448 (45.1%) of all patients reported at least one side effect of the 
treatment. 16 answers were invalid; 432 (43.5%) patients were in-
cluded into the analysis (table 3). They experienced mainly gastro-
intestinal symptoms 135 (13.6%), neurovegetative symptoms 107 
(10.8 %), temporary deteriorations of pain 88 (8.8%), diarrhoea 59 
(5.9%), nausea 16 (1.6%) and vomiting 5 (0.5%). 186 (18.7%) pa-
tients showed a various range of other symptoms. All participants 
were asked to attribute these side effects to certain interventions like 
decoctions of TCM drugs, acupuncture, tuina, qigong and others. 
The majority of 257 (59.4%) from 432 reporting patients and 38.6% 
of all patients respectively presumed a causative relation between 
side effects and decoctions (table 3). Diarrhoea, gastrointestinal and 
neurovegetative symptoms were the most commonly mentioned 
disorders in this perspective (table  3). Gastrointestinal symptoms 
appeared primarily as meteorism (flatulence) and abdominal pain. 
TCM decoctions were administered with 4 up to 5 prescriptions of 
individual herbs with a mean number of about 11 drugs (minimum 
Table 1. Reason for rejection: Investigations on microbial contamination, heavy metal load and pesticides; number of rejected samples: 5; total number of inves-
tigated samples: 23
Name of drug Identity Quality Concentration Purity Heavy metal  
load
Pesticides Microbiology Mycotoxcine
Aurantii immaturus  
fructus (Zhishi)
Ø Ø Ø Ø Ø Ø TAMC 4 × 108  
KBE/g
Ø
2 × Citri reticulatae  
pericarpium (Chenpi)
Ø Ø Ø Ø Ø dicofol:  
1.6 mg/kg;  
dicofol:  
3.6 mg/kg
Ø Ø
Lonicerae flos  
(Jin Yinhua)
Ø Ø Ø Ø lead (Pb);  
5.1mg/kg
fenpro- 
pathrin:  
0.05 mg/kg
Ø Ø
Bupleuri radix 
(Chaihu)
Ø Ø Ø Ø Ø Ø TAMC 5 ×108  
KBE/g; escherichia 
coli > 3 × 10³  
KBE/g
Ø
Standard values: lead ≤5.0 mg/kg; dicofol ≤ 0.5; fenpropathrin ≤ 0.03; TAMC≤5x107 KBE/g; TYMC ≤5 × 105 KBE/g; escherichia coli ≤103. 
Ø = normal finding. 
Table 2. Patient characteristics of the study sample (n = 994)
Patient characteristics
Gender
Female, % 72.6
Age in years, mean ± sd 52.6 ± 12.4
Less than 41 years old, % 13.5
41–60 years old, % 58.3
More than 60 years old, % 28.2
Principal diagnoses (ICD 10)
F54 psychological factors of different classified diseases, % 29.9
F45 somatoform disorder, % 20.9
F33 recurrent depression, % 14.2
F32 episode of depression, % 11.8
F43 maladaptation %  5.8
Additional diagnoses (ICD 10)
M54 back pain, % 36.0
I10 hypertension, % 20.4
F45 somatoform disorder, % 17.7
M79 chronic pain disorder in soft tissue, % 16.3
G47 sleep disturbances, % 12.9
Days spent in the hospital, mean ± sd 26.2 ± 5.2
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6 to maximum 19 components) during the hospital stay. Dose rate 
for each component was 6–10 g. Total dose rate per day and pre-
scription was about 95 g served in two decoctions a day. 
Further, we investigated the frequency of clinically relevant ele-
vated liver enzymes in all survey participants. Table  4 shows the 
number of patients at discharge with normal values and multiples 
of the upper normal limit N >1 <2, N>2, N >6 and N >10 of ALT 
and AST. 935 patients had normal values of liver enzymes at ad-
mission to the hospital. In 53 cases, laboratory results showed ele-
vated ALT values in the category of N >1 <2 of the upper normal 
limit. Two patients showed multiples of both N >2 and N >6 in 
ALT. In comparison, AST values were elevated only 2-fold in only 
two patients. One patient showed a more than 10-fold higher ex-
pression of ALT (table 4). 
Table 4 also shows the number of patients (n) at discharge with 
multiples of the increased value at admission (N) of ALT and AST. 
ALT and AST values measured in 46 and 28 patients, respectively, 
whose values were increased at admission, showed a slight eleva-
tion (N>1 < 2) in 44 and 25 cases, respectively. In the categories N 
>2 and N >3 only one patient each with increased ALT values was 
detected. In contrast, 3 patients each were detected with increased 
AST values (table  5). In 4 cases elevated ALT values improved 
slightly, but did not return to normal levels. 
Details of the 6 patients with a more than 2-fold elevation (com-
pared to maximum normal value or elevated admission values) of 
ALT are shown in table 5. Five female patients with different psy-
chosomatic disorders (ICD-9: F31-F54) and one male patient with 
colitis ulcerosa (ICD-9 K51.9) were affected by hepatotoxicity. Two 
of these patients showed increased liver enzymes at admission (pa-
tients 5 and 6). All 6 patients were treated with decoctions twice a 
day and 15–26 drugs with dose rates between 30 g and 102 g per 
day. In addition to TCM drugs, they all received conventional drug 
treatment that was initiated prior to admission. Most of the con-
ventional drugs (not in patient 2) have been associated with hepa-
totoxicity (celecoxib, mesalazin, pantoprazol, tocilizumab, zolpi-
dem). Patient 1 and 3 suffered from gastrointestinal symptoms, 
such as diarrhoea, meteorism and abdominal pain during the hos-
pital stay. In all patients, other causes of acute liver injury were ex-
cluded on a clinical level. Only patient 5 showed a history of hepa-
titis B. Control check-ups within the first 8 weeks after discharge 
and cessation of TCM drugs were denied by two patients (patient 4 
and 6). In patient 1 and 3 ALT values returned to normal; patient 2 
and 5 still had slight enhanced levels, but showed >50% decrease 
between ALT peak and N. CMD treatment was continued only in 
patient 5, after liver enzyme values returned to normal. A causal 
relationship between ALT elevation and TCM drug therapy was as-
sessed with CIOMS scale. Total scores of CIOMS scale ranged from 
0 to 3 points with a resulting causality rated as ‘possible’ for patient 
2; as ‘unlikely’ for patients 3–6; and as ‘excluded’ for patient 1.
To identify drugs which may be associated with an increased 
risk of ALT elevations, the frequencies of prescribed drugs in pa-
tients with elevated ALT values and in the 6 cases with more than 
2-fold elevated values respectively were compared with the pre-
scription pattern of all patients without elevated liver enzymes 
(table 6). Data of drug prescriptions were available from 876 pa-
tients 739 of which had normal ALT levels, 137 elevated values and 
6 more than 2-fold elevated values, respectively. Additionally, in 
383 patients self-reported side effects and frequency of prescribed 
drugs were matched with results from the other groups. Table  6 
demonstrates the most frequently prescribed herbs: Achyranthis 
bidentatae radix (63.5%), Paeoniae rubra radix (51.3%), Bupleuri 
radix (51.1%), Astragali radix (49.0%), Aurantii immaturus fructus 
(44.5%), Scutellariae radix (43.6%) and Dipsaci radix (41.1%). No 
noticeable differences regarding the frequency of prescribed drugs 
Table 3. Reported side effects of 432 patients between January 9, 2012 and December 31, 2013 (N = 994); multiple responses possible
Patients, n, % Diarrhoea,  
59 (5.9)
Nausea,  
16 (1.6)
Vomiting,  
5 (0.5)
Other  
gastrointestinal 
symptoms,  
135 (13.6)
Neurovegetative 
symptoms,  
107 (10.8)
Detoriation 
of pain,  
88 (8.8)
Others,  
186 (18.7)
Total,  
432 (43.5)
Decoction 46 11 4 103 61 36 104 257
Acupuncture  0  0 0   2 12   7  25
Tuina  0  0 0   0  5  8   9  18
Qigong  1  0 0   1  0  2   3   7
Others 12  5 1  29 33 30  63 125
Admission Discharge
Within normal* range normal N >1<2 N>2 N>6 N>10
ALT, n = 948 891 53 2 1 1
AST, n = 966 959  5 2 0 0
Above normal* range N >1<2 N>2 N>3
ALT, n = 46 44 1 1
AST, n = 28 25 3 0
*Norm limits of AST and ALT: 35 U/l (female); 50 U/l (male).
Table 4. Number of patients (n) with  
normal values and multiples of the upper normal 
limit (N) at  discharge with respect to alanine  
aminotransferase (ALT) and aspartate  
aminotransferase (AST); total  patients = 994
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between the groups were found. For Bupleuri radix a risk ratio 
(RR) of 0.19 (95% confidence interval (CI): 0.01–1.66) for a more 
than 2-fold ALT elevation could be derived. TheRR rates for Astra-
gali radix and Scutellariae radix were 5.21 (95% CI: 0.60–119.75) 
and 2.59 (95% CI: 0.41–20.24) respectively.
Finally, hepatotoxicity of the most important published TCM 
drugs was compared (table 7). In 4 and 3 of 6 patients with liver 
injury, (N >2 in ALT as the upper limit of normal) herbs with po-
tential hepatotoxicity, i.e. Scutellariae radix (Huanquin) and Rhei 
radix et rhizome (Dahuang), and Cassiae semen (Juemingzi) and 
Meliae toosendan fructus (Chuanlianzi) respectively were applied. 
Prescriptions containing Scutellariae radix and Rhei radix et rhi-
zome were administered to patient 2 and 6; patient 3 received all 4 
suspicious drugs during hospital stay for more than 4 weeks. 
Name of drug Patients without  
elevation, n = 739
Patients with  
elevated liver  
enzymes, n = 137
Patients with  
more than 2-fold  
elevation, n = 6
Patients with  
subjective adverse  
reactions, n = 383
n % n % n % n %
Achyranthis bidentatae radix 476 64,4 80 61.1 5 83.3 242 63.2
Paeoniae rubra radix 382 51,7 67 51.1 5 83.3 201 52.5
Bupleuri radix 385 52,1 63 48.1 1 16.7 204 53.3
Astragali radix 373 50,5 56 42.7 5 83.3 194 50.7
Aurantii immaturus fructus 344 46,5 46 35.1 3 50.0 173 45.2
Scutellariae radix 323 43,7 59 45.0 4 66.7 176 46.0
Dipsaci radix 298 40,3 62 47.3 4 66.7 159 41.5
Ligustici chuanxiong rhizoma 294 39,8 50 38.2 2 33.3 149 38.9
Loranthi ramulus 278 37,6 58 44.3 3 50.0 147 38.4
Aurantii fructus 284 38,4 33 25.2 1 16.7 142 37.1
Sparganii tuber (rhizoma) 278 37,6 38 29.0 2 33.3 140 36.6
Bambusae caulis in taeniam 258 34,9 49 37.4 2 33.3 146 38.1
Poria (Stücke) 241 32,6 43 32.8 1 16.7 118 30.8
Curcumae longae rhizoma 239 32,3 37 28.2 4 66.7 118 30.8
Ligustri lucidi fructus 226 30,6 39 29.8 1 16.7 116 30.3
Coicis semen 208 28,1 44 33.6 1 16.7 117 30.5
Atractylodis rhizoma 215 29,1 36 27.5 3 50.0 111 29.0
Citri reticulatae pericarpium 214 29,0 32 24.4 1 16.7 127 33.2
Magnoliae officinalis cortex 185 25,0 34 26.0 1 16.7 111 29.0
Cinnamomi ramulus 170 23,0 46 35.1 1 16.7  91 23.8
Notopterygii rhizoma seu radix 172 23,3 40 30.5 0 100 26.1
Angelicae pubescentis radix 168 22,7 41 31.3 0  99 25.8
Liquidambaris fructus 173 23,4 27 20.6 2 33.3  81 21.1
Mori ramulus 152 20,6 38 29.0 1 16.7  85 22.2
Curcumae radix 151 20,4 18 13.7 2 33.3  76 19.8
Cuscutae semen 143 19,4 22 16.8 0  66 17.2
Paeoniae alba radix 143 19,4 17 13.0 0  67 17.5
Pinelliae praeparatae rhizoma 134 18,1 18 13.7 2 33.3  66 17.2
Lycii fructus 120 16,2 17 13.0 1 16.7  50 13.1
Tribuli fructus 122 16,5 13  9.9 0  62 16.2
Angelicae dahuricae radix 120 16,2 12  9.2 0  66 17.2
Angelicae sinensis radix 108 14,6 17 13.0 0  52 13.6
Corydalis rhizoma 111 15,0 13  9.9 0  56 14.6
Spatholobi caulis 107 14,5 12  9.2 0  68 17.8
Persicae semen 100 13,5 17 13.0 0  57 14.9
Lumbricus (t) 107 14,5  9  6.9 1 16.7  47 12.3
Polygalae radix 103 13,9 12  9.3 0  45 11.7
Albiziae cortex 101 13,7 12  9.3 0  46 12.0
Lycopodii herba  99 13,4 14 10.7 0  50 13.1
Carthami flos 106 14,3  6  4.7 0  51 13.1
Codonopsis pilosulae radix  92 12,4 20 15.3 2 33.3  58 15.1
Epimedii herba  94 12,7 14 10.7 1 16.7  55 14.4
Meliae toosendan fructus  85 11,5 17 13.0 1 16.7  51 13.3
Ledebouriellae radix  88 11,9 10  7.6 1 16.7  44 11.5
Phellodendri cortex  83 11,2  6  4.6 0  39 10.2
Lycopi herba  79 10,7  6  4.6 0  31  8.1
Prunella spica  30  4,1 11  8.5 0  16  4.2
Pyrrosiae folium   6  8  4  3.1 0   2  0.5
Table 6. Most  
frequently prescribed 
drugs in all 739  
patients with normal 
values vs. 137 patients 
with elevated values of 
liver enzymes vs 383 
patients with side  
effects
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Discussion
Plants are natural producers of chemical substances, enabling 
treatment of human ailments since ancient times. Many of them 
are harmless or have only minor and transient adverse effects. 
Some herbal chemicals in medicinal plants of traditional and mod-
ern medicine, however, carry the risk of herb-induced liver injury 
(HILI) when given in high concentrations, and some even when 
used in recommended doses [12, 13]. In many cases, the specific 
TCM drug that is responsible for the liver injury is unclear. In 
order to ensure the quality of the TCM drugs given to the patients 
at the TCM hospital Bad Kötzting, a comprehensive pretreatment 
drug control program as well as a complication screening program 
has been installed. Gastrointestinal symptoms, hepatotoxicity and 
interactions causing elevated or decreased drug levels of main-
stream medical drugs are some of the safety information that 
should be given by administering TCM drugs to admitted patients. 
Since herbal medicines contain more than one pharmacologically 
active ingredient and are commonly used in combination with 
other prescribed herbal and conventional drugs, there is a risk of 
potential herb-drug interactions which might lead to serious clini-
cal consequences [14]. Concurrent administration of herbal and 
conventional medicines was found in the majority of patients and 
was maintained in the course of their hospital stay, if necessary. 
Despite safety concerns, Chinese medicine appears to be relatively 
safe with comparatively few reports of adverse reactions compared 
with overall drug reports. A recent prospective population-based 
study from Iceland [15] found an annual incidence rate of drug-
induced liver injury (DILI) of approximately 19 cases per 100,000 
habitants per year. The most commonly implicated drugs in this 
general population were amoxicillin-clavulanate (22%), diclofenac 
(6%), azathioprine (4%), infliximab (4%), and nitrofurantoin (4%). 
The median duration of therapy was 20 days (range, 8–77 days). 
The use of some herbal TCM products carries the rare risk of liver 
injury [11, 16]. At present, the English literature refers to about 40 
single TCM herbs with potential hepatotoxicity [3, 11]. A recent 
review of Teschke et.al [3] gives a good overview of potentially 
harmful TCM drugs also used for comparison in our survey. Nev-
ertheless, a list of these drugs still has to be rated carefully. Espe-
cially drugs with a high prescription rate, such as Scutellariae radix 
(Huanquin) and Bupleuri radix (Chaihu), have a RR with an ex-
tremely broad CI (Scutellariae radix: 2.59 (95% CI: 0.41–20.24); 
Bupleuri radix: 0.19 (95%CI: 0.01–1.66).
Based on our data of 994 inpatients admitted to the hospital be-
tween September 1, 2012 and December 31, 2013, we assessed the 
patient-perceived occurrence of reported side effects. The adverse 
reaction reporting system revealed that 17.6% of all inpatients of the 
hospital reported gastrointestinal symptoms. 5.7 % of these patients 
are afflicted by diarrhea, mostly induced by applied decoctions. The 
reporting system lacks precoded complication lists and thus must be 
Reported hepatotoxicity of TCM drugs /  
name of drug
Total patient  
sample, n = 876
Patients with  
elevated liver  
enzymes, n = 137
Patients with  
more than 2-fold  
elevation, n = 6
Patients with  
subjective adverse  
reactions, n = 383
n % n % n % n %
Agkistrodon (t)/Qishe   0  0 0   0
Alismatis rhizoma/Zexie  30  3.4  4  3.1 0  10  2.6
Artemisia capillaris/yinchen hao   0  0 0   0
Bombyx batryticatus (t)/Baijiangcan  58  6.6  4  3.1 0  25  6.5
Bupleurum/chaihu 448 51.1 63 48.2 0 201 53.3
Cassiae semen/Juemingzi (senna)  40  4.6  3  2.3 1 16.7  16  4.2
Dictamni radicis cortex/Baixianpi  22  2.5  2  1.6 0  12  3.1
Ephedrae herba/Mahuang  17  1.9  2  1.6 0   6  1.6
Galla chinensis/Wubeizi   3  0.3  0 0   1  0.3
Ginseng radix/Renshen   1  0.1  1  0.8 0   0
Glycyrrhizae radix/gancao  16  1.8  0 0   7  1.8
Meliae toosendan fructus/Chuanlianzi 102 11.6 17 13.2 1 16.7  51 13.3
Menthae herba/Bohe  58  6.6  7  5.3 0  22  5.7
Oldenlandiae diffusa herba/Baihuasheca   1  0.1  1  0.8 0   0
Polygoni cuspidati rhizoma/Huzhang   0  0 0   0
Polygoni multiflora caulis/Shouwuteng  31  3.5  1  0.8 0  13  3.5
Polygoni multiflori radix/Heshouwu   4  0.5  0 0   0
Puerariae radix/Gegen  35  4.0  8  6.2 0  12  3.1
Punicae granati pericarpium/Shiliupi   0  0 0   0
Psoraleae fructus/buguzhi  33  3.8  8  6.2 0  15  3.9
Rhei radix et rhizoma/Dahuang  74  8.4 12  9.3 3 50.0  41 10.7
Rheum palmatum/Dahuang   0  0 0   0
Scolopendra (t)/Wugong   0  0 0   0
Scorpio Buthus martensii/Quanxie   3  0.3  0 0   1  0.3
Scutellariae radix/Huangqin 382 43.6 59 45.0 4 66.7 146 46.0
Trichosanthis radix/Tianhuafen   1  0.1 11  8.5 0   0
Tripterygii wilfordii radix/Leigongteng   0  0 0   0
Xanthii fructus/Cangerzi  19  2.0  3  2.3 0   5  1.3
Table 7. TCM drugs 
showing potential 
hepatotoxicity;  
frequency of their use 
in TCM hospital;  
frequency in patients 
with elevated liver  
enzymes and patient-
reported adverse  
reactions, respectively
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completed by half-structured interviews. Liver injury was assessed 
based on ALT levels that were more than 2-fold above the upper 
limit of normal. 6 from 994 patients within the observational times-
pan fulfilled this definition. Patients were advised to cease all supple-
ment use and were monitored for signs of significant liver dysfunc-
tion. Drug discontinuation and therapy reconciliation are the main 
measures in patient management to minimize occurrence of acute 
liver failure. To identify the nature and components of the liver in-
jury, characterisation of the clinical phenotype or pattern of hepatic 
injury is helpful [10]. Differentiation between hepatocellular, choles-
tatic or mixed type hepatotoxicity is facilitated by comparing initial 
ALT and ALP values (ALP serum activities) [3, 11]. Unfortunately, 
the management of the complication screening program did not yet 
provide serum level of ALP routinely – a must for the future. 
Although side effects decreased in all patients and liver enzyme 
levels normalised after discontinuing TCM drugs, the hospital is 
committed to inform patients according to the Summary of Prod-
uct Characteristics (SPC) guideline. Liver injury occurs in ≥1/1,000 
to ≤1/100 cases (uncommon adverse reaction); symptoms of diar-
rhea occur in ≥1/100 to <1/10 cases (common adverse event). 
Risks should be identified and communicated to the academic 
and medical public. As in conventional pharmaceuticals, the confi-
dence with which a TCM diagnosis of liver injury is made depends 
to a great extent on the number of previously reported and pub-
lished cases [17]. Nevertheless, scientific strategy has to keep an eye 
on a fair benefit-risk ratio in order to balance both impact factors 
of medical care. Therefore, more financial support from political 
and research funding authorities is needed to realise a better frame-
work for clinical research. 
We assessed the occurrence rate and causality levels according 
to the criteria of CIOMS (Council for International Organizations 
of Medical Sciences) scale which is a suitable instrument for cau-
sality assessment within clinical routine. Surprisingly, all patients 
involved in the study showed only a few points on the CIOMS 
scale. A systematic data collection assessing continued drug ther-
apy after normalisation of the liver enzymes is still pending and a 
further challenge for the complication screening programme. 
The results comparing the frequency and quality of drug pre-
scriptions in the different groups of the survey have to be interpreted 
with great caution. There is no simple correlation between the num-
ber of cases in which a single drug has been prescribed and an in-
creased risk of adverse events or liver toxicity. An exception could be 
shown in the analysis of different frequencies of drug prescriptions 
in the groups ‘all patients’ and ‘patients with liver injury’. 
The aim of the quality control program of TCM drugs is to 
avoid adulteration and contamination of herbal medicinal prod-
ucts. A few years back, the results of the examinations revealed 
more problems associated with drug contents than with contami-
nation [18]. Nowadays, troubles with contamination are more 
prominent. The spectrum of contaminations contains dust, fungi, 
insects, microbes, rodents, parasites, pesticides, toxic heavy metals 
and/or mainstream drugs [18]. Present examinations of our survey 
show that heavy metals and pesticides are the most striking con-
taminants. All mistaken and contaminated drugs were rejected 
from the routine administration. 
Conclusion 
Further research on safety of and compliance with traditional 
Chinese drug treatment is clearly warranted in order to find and 
teach strategies by which these problems can be anticipated, pre-
vented, or managed. 
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